NEJM spotlights Provenge study
This is a discussion on NEJM spotlights Provenge study within the Biotechnology News forum, part of the Industry News and Updates category; Shares of Dendreon ( NASDAQ: DNDN ) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
07-29-2010, 12:38 PM
|
|||
|
|||
NEJM spotlights Provenge study
Shares of Dendreon (NASDAQ: DNDN) soared into the stratosphere in the lead-up to Provenge's approval--and then promptly started tumbling fast as all sorts of questions arose about supply issues, cost and efficacy. But the company is likely to benefit enormously from the publication of its biggest study of the innovative prostate cancer vaccine in the prestigious New England Journal of Medicine, which carries biblical weight with providers. Story
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Zoledronic Acid Benefit in Breast Cancer: Data Published in NEJM | industry_news | Other Clinical Pharmacy News | 0 | 02-11-2009 07:14 PM |
© 2008 DrugManagementForum™ powered by |
 |